Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

Inclusion Criteria:

1. Participants must be ≥18 years of age .

2. Participants have a confirmed diagnosis of psoriatic arthritis (PsA) per the 2006Classification for Psoriatic Arthritis (CASPAR) criteria with symptoms for ≥6 monthsbefore the Screening Visit.

3. Participants have active disease (defined by a 68 tender joint count [TJC68] of ≥3and a 66 swollen joint count [SJC66] of ≥3).

4. Participants have current active plaque psoriasis (PsO) or a dermatologist-confirmedhistory of plaque PsO.

5. Participants test negative for both rheumatoid factor and anti-cyclic citrullinatedpeptide at the Screening Visit.

6. Participants must have received 1 or more TNFα inhibitors for PsA or PsO and musthave experienced an inadequate response to treatment with at least one TNFαinhibitor(s) given at an approved dose for ≥3 months or have stopped treatment dueto safety/tolerability problems after ≥1 administration of a TNFα inhibitor.

Exclusion Criteria:

1. Participants with a known hypersensitivity to sonelokimab or any of its excipients.

2. Participants with a known hypersensitivity, or any contraindication, to risankizumabor any of its excipients or component of the container.

3. Participants who have a diagnosis of chronic inflammatory conditions other than PsOor PsA.

4. Participants with a diagnosis of inflammatory bowel disease.

5. Participants who have experienced a period of ≥3 consecutive weeks of unexplaineddiarrhea in the 24 weeks before the Baseline Visit.

6. Participants who have an established diagnosis of arthritis mutilans.

7. Previous exposure to sonelokimab.

8. Participants who have ever received biologic immunomodulating agents for PsA or PsOwhether investigational or approved, except for those targeting TNFα